We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CAH Q1 Earnings Call Highlights Raised Outlook and Specialty Growth
Read MoreHide Full Article
Key Takeaways
CAH raises fiscal 2027 EPS guidance to $12.80-$13.00 after Q1 earnings of $3.26 per share beat estimates.
Specialty revenues rose 18%, while generics strength helped drive 17% pharmaceutical segment profit growth.
Cardinal Health renewed contracts covering nearly two-thirds of revenues; medical segment profit fell 28%.
Cardinal Health, Inc. (CAH - Free Report) raised its fiscal 2027 earnings outlook following a strong first quarter, supported by specialty pharmaceutical demand, generics performance and growth across its diversified businesses.
Management emphasized operating discipline, long-term customer renewals and targeted investments during the earnings call. Executives also addressed pharmaceutical reimbursement changes, medical distribution pressures and acquisition priorities.
CAH Raises Fiscal 2027 Outlook
Chief financial officer Aaron Alt raised fiscal 2027 non-GAAP earnings guidance to $12.80-$13.00 per share from $12.40-$12.60, representing 17%-19% growth against the adjusted fiscal 2026 baseline.
Pharmaceutical and Specialty Solutions profit growth expectations increased to 10%-12% from 8%-11%. Management anticipates earnings growth moderating during the second and third quarters before strengthening in the fourth quarter.
First-quarter adjusted earnings came in at $3.26 per share, exceeding the Zacks Consensus Estimate of $2.92. Revenues totaled $67.51 billion, surpassing the consensus estimate of $66.96 billion.
Cardinal Health, Inc. Price, Consensus and EPS Surprise
Alt reported 6% pharmaceutical revenue growth, supported by brand and specialty sales. Specialty expanded 18%, while GLP-1 medications contributed approximately 500 basis points to revenue growth.
However, Inflation Reduction Act-related wholesale acquisition cost reductions created a 400-basis-point revenue headwind. Pharmaceutical segment profit increased 17%, supported by generics and specialty contributions.
During Morgan Stanley's questioning, Alt highlighted strong specialty demand in oncology and urology. He also noted generic volumes exceeding long-term targets and continued benefits from Red Oak Sourcing.
CAH Strengthens Customer Contract Visibility
Chief executive officer Jason Hollar highlighted the CVS Health distribution renewal through June 2032, reinforcing an important long-term commercial relationship.
Hollar explained that contracts representing nearly two-thirds of enterprise revenues were renewed over the preceding 12 months, including major pharmaceutical and medical distribution customers.
Responding to Nephron Research, Hollar distinguished the Red Oak sourcing arrangement from the distribution renewal. He expressed confidence in continued collaboration beyond 2029 while acknowledging that renewal discussions remain necessary.
Cardinal Health Faces Medical Distribution Pressures
Global Medical Products and Distribution revenues remained approximately flat at $3.2 billion, while segment profit declined 28% to $33 million.
Alt indicated that elevated petroleum costs associated with the Iran conflict were pushing expected fiscal 2027 segment profit toward the lower end of the unchanged $200 million-$220 million guidance range.
Management continues pursuing distribution network optimization, automation and Cardinal Health Brand expansion. Alt expects second-quarter profitability to remain broadly consistent with the first quarter before sequential improvements.
CAH Expands Its Specialty and Home-Care Platforms
The Other businesses delivered 7% revenue growth and 16% profit growth. Management raised fiscal 2027 profit growth expectations to 17%-20%, reflecting stronger demand across at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics.
Hollar discussed the integration of Strive Medical and ongoing Solaris integration, emphasizing opportunities to connect urology services across pharmaceutical distribution, physician practice support and home-based care.
During Leerink Partners' questioning, Hollar described these complementary capabilities as incremental growth opportunities rather than individually transformative drivers. Management also anticipates completing the AdaptHealth Diabetes Health acquisition during fiscal 2027's third quarter.
Cardinal Health Addresses Regulatory Uncertainty
Deutsche Bank questioned whether reimbursement changes involving 340B could shift patient volumes between care settings.
Hollar acknowledged uncertainty around the magnitude of potential shifts but maintained that Cardinal Health could participate in volume redistribution through its existing market presence.
Management also reaffirmed disciplined capital allocation, supported by expected fiscal 2027 adjusted free cash flow of $3.5 billion-$4 billion and continued investments in operational capabilities.
CAH Maintains Its Strategic Focus
Hollar emphasized strengthening pharmaceutical distribution, scaling specialty capabilities and improving medical distribution profitability while maintaining disciplined acquisition criteria.
Alt reinforced management's focus on sustainable operating improvements and financial flexibility. The updated outlook reflects confidence in continued demand alongside acknowledged medical distribution cost pressures.
CAH’s Zacks Rank and Style Scores Signal
Cardinal Health currently carries a Zacks Rank #3 (Hold). Its Value and Growth Style Scores are both A, indicating favorable characteristics across those investment styles, while its Momentum Score of C reflects a comparatively moderate momentum profile.
The company's VGM Score of A indicates attractive combined value, growth and momentum characteristics. However, Zacks' framework generally emphasizes pairing favorable Style Scores with a Zacks Rank #1 (Strong Buy) or #2 (Buy). Cardinal Health's current Rank reflects a more neutral near-term outlook and remains subject to changes as earnings estimates are revised following the reported results. You can see the complete list of today’s Zacks #1 Rank stocks here.
View the Zacks #1 Rank List
Image: Bigstock
CAH Q1 Earnings Call Highlights Raised Outlook and Specialty Growth
Key Takeaways
Cardinal Health, Inc. (CAH - Free Report) raised its fiscal 2027 earnings outlook following a strong first quarter, supported by specialty pharmaceutical demand, generics performance and growth across its diversified businesses.
Management emphasized operating discipline, long-term customer renewals and targeted investments during the earnings call. Executives also addressed pharmaceutical reimbursement changes, medical distribution pressures and acquisition priorities.
CAH Raises Fiscal 2027 Outlook
Chief financial officer Aaron Alt raised fiscal 2027 non-GAAP earnings guidance to $12.80-$13.00 per share from $12.40-$12.60, representing 17%-19% growth against the adjusted fiscal 2026 baseline.
Pharmaceutical and Specialty Solutions profit growth expectations increased to 10%-12% from 8%-11%. Management anticipates earnings growth moderating during the second and third quarters before strengthening in the fourth quarter.
First-quarter adjusted earnings came in at $3.26 per share, exceeding the Zacks Consensus Estimate of $2.92. Revenues totaled $67.51 billion, surpassing the consensus estimate of $66.96 billion.
Cardinal Health, Inc. Price, Consensus and EPS Surprise
Cardinal Health, Inc. price-consensus-eps-surprise-chart | Cardinal Health, Inc. Quote
Cardinal Health Sees Sustained Pharma Momentum
Alt reported 6% pharmaceutical revenue growth, supported by brand and specialty sales. Specialty expanded 18%, while GLP-1 medications contributed approximately 500 basis points to revenue growth.
However, Inflation Reduction Act-related wholesale acquisition cost reductions created a 400-basis-point revenue headwind. Pharmaceutical segment profit increased 17%, supported by generics and specialty contributions.
During Morgan Stanley's questioning, Alt highlighted strong specialty demand in oncology and urology. He also noted generic volumes exceeding long-term targets and continued benefits from Red Oak Sourcing.
CAH Strengthens Customer Contract Visibility
Chief executive officer Jason Hollar highlighted the CVS Health distribution renewal through June 2032, reinforcing an important long-term commercial relationship.
Hollar explained that contracts representing nearly two-thirds of enterprise revenues were renewed over the preceding 12 months, including major pharmaceutical and medical distribution customers.
Responding to Nephron Research, Hollar distinguished the Red Oak sourcing arrangement from the distribution renewal. He expressed confidence in continued collaboration beyond 2029 while acknowledging that renewal discussions remain necessary.
Cardinal Health Faces Medical Distribution Pressures
Global Medical Products and Distribution revenues remained approximately flat at $3.2 billion, while segment profit declined 28% to $33 million.
Alt indicated that elevated petroleum costs associated with the Iran conflict were pushing expected fiscal 2027 segment profit toward the lower end of the unchanged $200 million-$220 million guidance range.
Management continues pursuing distribution network optimization, automation and Cardinal Health Brand expansion. Alt expects second-quarter profitability to remain broadly consistent with the first quarter before sequential improvements.
CAH Expands Its Specialty and Home-Care Platforms
The Other businesses delivered 7% revenue growth and 16% profit growth. Management raised fiscal 2027 profit growth expectations to 17%-20%, reflecting stronger demand across at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics.
Hollar discussed the integration of Strive Medical and ongoing Solaris integration, emphasizing opportunities to connect urology services across pharmaceutical distribution, physician practice support and home-based care.
During Leerink Partners' questioning, Hollar described these complementary capabilities as incremental growth opportunities rather than individually transformative drivers. Management also anticipates completing the AdaptHealth Diabetes Health acquisition during fiscal 2027's third quarter.
Cardinal Health Addresses Regulatory Uncertainty
Deutsche Bank questioned whether reimbursement changes involving 340B could shift patient volumes between care settings.
Hollar acknowledged uncertainty around the magnitude of potential shifts but maintained that Cardinal Health could participate in volume redistribution through its existing market presence.
Management also reaffirmed disciplined capital allocation, supported by expected fiscal 2027 adjusted free cash flow of $3.5 billion-$4 billion and continued investments in operational capabilities.
CAH Maintains Its Strategic Focus
Hollar emphasized strengthening pharmaceutical distribution, scaling specialty capabilities and improving medical distribution profitability while maintaining disciplined acquisition criteria.
Alt reinforced management's focus on sustainable operating improvements and financial flexibility. The updated outlook reflects confidence in continued demand alongside acknowledged medical distribution cost pressures.
CAH’s Zacks Rank and Style Scores Signal
Cardinal Health currently carries a Zacks Rank #3 (Hold). Its Value and Growth Style Scores are both A, indicating favorable characteristics across those investment styles, while its Momentum Score of C reflects a comparatively moderate momentum profile.
The company's VGM Score of A indicates attractive combined value, growth and momentum characteristics. However, Zacks' framework generally emphasizes pairing favorable Style Scores with a Zacks Rank #1 (Strong Buy) or #2 (Buy). Cardinal Health's current Rank reflects a more neutral near-term outlook and remains subject to changes as earnings estimates are revised following the reported results. You can see the complete list of today’s Zacks #1 Rank stocks here.